Cytotoxic activity of azulenequinones against human oral tumor cell lines. 2005

Hidetsugu Wakabayashi, and Masayuki Nishishiro, and Satomi Arikawa, and Ken Hashimoto, and Hirotaka Kikuchi, and Hirofumi Nishikawa, and Teruo Kurihara, and Shigemi Terakubo, and Yoko Shoji, and Hideki Nakashima, and Noboru Motohashi, and Hiroshi Sakagami
Faculty of Science, Josai University, Sakado, Saitama, Japan. hwaka@josai.ac.jp

We investigated twenty-seven azulenequinone derivatives for their relative cytotoxicity against three human normal cell lines (HGF, HPC, HPLF) and four human tumor cell lines (HSG, HSC-2, HSC-3, HL-60). Parent 1,5-azulenequinone showed potent and some tumor-specific cytotoxicity. Halogenated derivatives of 1,5- and 1,7-azulenequinone showed potent cytotoxicity, but lower tumor-specific cytotoxicity. In contrast to other azulenequinones, amino derivatives such as 3-amino-1,5- and 1, 7-azulenequinones showed relatively lower cytotoxic activity. The 3-Phenoxy-1,5-azuleneqinone derivative showed higher cytotoxicity than the 3-phenoxy-1, 7-azulenequinone derivative. 1,5- and 1,7-Azulenequinones generally showed higher cytotoxicity, as compared with tropolones and azulene derivatives. 3- (3-Guaiazulenyl)-1, 5-azulenequinone [12] and 7-isopropyl-3- (4-methylanilino)-2-methyl- 1, 5-azulenequinone [24] showed a relatively higher TS value and induced apoptosis (internucleosomal DNA fragmentation, activation of caspases 3, 8 and 9) in HL-60 and HSC-2 cells, possibly via the activation of both mitochondria-independent (extrinsic) and -dependent (intrinsic) pathways. Western blot analysis showed that [24] slightly increased the intracellular concentration of pro-apoptotic proteins (Bad, Bax) in HSC-2 cells, whereas [12] was much less active. None of the twenty-seven azulenequinones showed anti-HIV activity. These results suggest [12] and [24] as possible candidates for future cancer chemotherapy.

UI MeSH Term Description Entries
D009062 Mouth Neoplasms Tumors or cancer of the MOUTH. Cancer of Mouth,Mouth Cancer,Oral Cancer,Oral Neoplasms,Cancer of the Mouth,Neoplasms, Mouth,Neoplasms, Oral,Cancer, Mouth,Cancer, Oral,Cancers, Mouth,Cancers, Oral,Mouth Cancers,Mouth Neoplasm,Neoplasm, Mouth,Neoplasm, Oral,Oral Cancers,Oral Neoplasm
D011809 Quinones Hydrocarbon rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D003508 Cycloheptanes Seven-carbon cycloparaffin cycloheptane (the structural formula (CH2)7) and its derivatives.
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Hidetsugu Wakabayashi, and Masayuki Nishishiro, and Satomi Arikawa, and Ken Hashimoto, and Hirotaka Kikuchi, and Hirofumi Nishikawa, and Teruo Kurihara, and Shigemi Terakubo, and Yoko Shoji, and Hideki Nakashima, and Noboru Motohashi, and Hiroshi Sakagami
January 2001, Anticancer research,
Hidetsugu Wakabayashi, and Masayuki Nishishiro, and Satomi Arikawa, and Ken Hashimoto, and Hirotaka Kikuchi, and Hirofumi Nishikawa, and Teruo Kurihara, and Shigemi Terakubo, and Yoko Shoji, and Hideki Nakashima, and Noboru Motohashi, and Hiroshi Sakagami
January 2003, Anticancer research,
Hidetsugu Wakabayashi, and Masayuki Nishishiro, and Satomi Arikawa, and Ken Hashimoto, and Hirotaka Kikuchi, and Hirofumi Nishikawa, and Teruo Kurihara, and Shigemi Terakubo, and Yoko Shoji, and Hideki Nakashima, and Noboru Motohashi, and Hiroshi Sakagami
January 2003, Anticancer research,
Hidetsugu Wakabayashi, and Masayuki Nishishiro, and Satomi Arikawa, and Ken Hashimoto, and Hirotaka Kikuchi, and Hirofumi Nishikawa, and Teruo Kurihara, and Shigemi Terakubo, and Yoko Shoji, and Hideki Nakashima, and Noboru Motohashi, and Hiroshi Sakagami
January 2000, Anticancer research,
Hidetsugu Wakabayashi, and Masayuki Nishishiro, and Satomi Arikawa, and Ken Hashimoto, and Hirotaka Kikuchi, and Hirofumi Nishikawa, and Teruo Kurihara, and Shigemi Terakubo, and Yoko Shoji, and Hideki Nakashima, and Noboru Motohashi, and Hiroshi Sakagami
January 2001, Anticancer research,
Hidetsugu Wakabayashi, and Masayuki Nishishiro, and Satomi Arikawa, and Ken Hashimoto, and Hirotaka Kikuchi, and Hirofumi Nishikawa, and Teruo Kurihara, and Shigemi Terakubo, and Yoko Shoji, and Hideki Nakashima, and Noboru Motohashi, and Hiroshi Sakagami
January 2000, Anticancer research,
Hidetsugu Wakabayashi, and Masayuki Nishishiro, and Satomi Arikawa, and Ken Hashimoto, and Hirotaka Kikuchi, and Hirofumi Nishikawa, and Teruo Kurihara, and Shigemi Terakubo, and Yoko Shoji, and Hideki Nakashima, and Noboru Motohashi, and Hiroshi Sakagami
January 2005, In vivo (Athens, Greece),
Hidetsugu Wakabayashi, and Masayuki Nishishiro, and Satomi Arikawa, and Ken Hashimoto, and Hirotaka Kikuchi, and Hirofumi Nishikawa, and Teruo Kurihara, and Shigemi Terakubo, and Yoko Shoji, and Hideki Nakashima, and Noboru Motohashi, and Hiroshi Sakagami
March 2000, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Hidetsugu Wakabayashi, and Masayuki Nishishiro, and Satomi Arikawa, and Ken Hashimoto, and Hirotaka Kikuchi, and Hirofumi Nishikawa, and Teruo Kurihara, and Shigemi Terakubo, and Yoko Shoji, and Hideki Nakashima, and Noboru Motohashi, and Hiroshi Sakagami
January 2001, Anticancer research,
Hidetsugu Wakabayashi, and Masayuki Nishishiro, and Satomi Arikawa, and Ken Hashimoto, and Hirotaka Kikuchi, and Hirofumi Nishikawa, and Teruo Kurihara, and Shigemi Terakubo, and Yoko Shoji, and Hideki Nakashima, and Noboru Motohashi, and Hiroshi Sakagami
January 2001, Anticancer research,
Copied contents to your clipboard!